Dioxaphetyl butyrate

Dioxaphetyl butyrate
Clinical data
Other namesAmidalgon, Spasmoxal
Routes of
administration
Oral, Other ROA Unknown
ATC code
  • none
Legal status
Legal status
Identifiers
  • Ethyl 4-morpholin-4-yl-2,2-di(phenyl)butanoate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.006.731 Edit this at Wikidata
Chemical and physical data
FormulaC22H27NO3
Molar mass353.462 g·mol−1
3D model (JSmol)
  • CCOC(=O)C(CCN1CCOCC1)(c1ccccc1)c1ccccc1
  • InChI=1S/C22H27NO3/c1-2-26-21(24)22(19-9-5-3-6-10-19,20-11-7-4-8-12-20)13-14-23-15-17-25-18-16-23/h3-12H,2,13-18H2,1H3 ☒N
  • Key:LQGIXNQCOXNCRP-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Dioxaphetyl butyrate (INN; trade names Amidalgon, Spasmoxal) is an opioid analgesic which is a diphenylacetic acid derivative, related to other open-chain opioid drugs such as dextropropoxyphene, levacetylmethadol (LAAM), lefetamine and dimenoxadol.[2][3]

It produces similar effects to other opioids, including dependence, euphoria, analgesia, sedation, constipation, dizziness and nausea.[4]

In the United States it is a Schedule I Narcotic controlled substance with an ACSCN of 9621 and a 2013 annual aggregate manufacturing quota of zero.[5]

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ "Dioxaphetyl butyrate". PubChem. U.S. National Library of Medicine. Retrieved 2019-06-03.
  3. ^ "Dioxaphetyl butyrate | C22H27NO3". ChemSpider. Retrieved 2019-06-03.
  4. ^ "Dioxaphetyl butyrate". drugcentral.org. Retrieved 2019-06-03.
  5. ^ "Misuse of Drugs Act : Legislative history · Part I Class A · Section 1(a): Explicitly named Class A substances". isomerdesign.com. Retrieved 2019-06-03.